RU2017112747A - Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции - Google Patents
Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции Download PDFInfo
- Publication number
- RU2017112747A RU2017112747A RU2017112747A RU2017112747A RU2017112747A RU 2017112747 A RU2017112747 A RU 2017112747A RU 2017112747 A RU2017112747 A RU 2017112747A RU 2017112747 A RU2017112747 A RU 2017112747A RU 2017112747 A RU2017112747 A RU 2017112747A
- Authority
- RU
- Russia
- Prior art keywords
- quinidine
- treatment
- dementia
- dextrometorphanic
- demenium
- Prior art date
Links
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 title claims 12
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 title claims 6
- 229960001404 quinidine Drugs 0.000 title claims 6
- 150000001875 compounds Chemical class 0.000 title 1
- 230000005284 excitation Effects 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 206010012289 Dementia Diseases 0.000 claims 8
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical class C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims 5
- 208000024827 Alzheimer disease Diseases 0.000 claims 4
- 230000016571 aggressive behavior Effects 0.000 claims 4
- 230000037007 arousal Effects 0.000 claims 4
- 208000024891 symptom Diseases 0.000 claims 4
- 238000000034 method Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/22—Bridged ring systems
- C07D221/28—Morphinans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (8)
1. Способ лечения возбуждения и/или агрессии и/или связанных с ними симптомов у пациента с деменцией, включающий введение нуждающемуся в этом пациенту дейтерированного декстрометорфана и хинидина.
2. Способ по п.1, в котором типом деменции является болезнь Альцгеймера.
3. Дейтерированный декстрометорфан и хинидин для применения в лечении возбуждения и/или агрессии и/или связанных с ними симптомов у пациента с деменцией.
4. Дейтерированный декстрометорфан и хинидин по п.3, где типом деменции является болезнь Альцгеймера.
5. Применение дейтерированного декстрометорфана и хинидина для лечения возбуждения и/или агрессии и/или связанных с ними симптомов у пациента с деменцией.
6. Применение по п.5, где типом деменции является болезнь Альцгеймера.
7. Применение дейтерированного декстрометорфана и хинидина для получения лекарственного средства для лечения возбуждения и/или агрессии и/или связанных с ними симптомов у пациента с деменцией.
8. Применение по п.7, где типом деменции является болезнь Альцгеймера.
Applications Claiming Priority (35)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050170P | 2014-09-14 | 2014-09-14 | |
| US62/050,170 | 2014-09-14 | ||
| US201462061451P | 2014-10-08 | 2014-10-08 | |
| US62/061,451 | 2014-10-08 | ||
| US201462063122P | 2014-10-13 | 2014-10-13 | |
| US62/063,122 | 2014-10-13 | ||
| US201462063861P | 2014-10-14 | 2014-10-14 | |
| US62/063,861 | 2014-10-14 | ||
| US201462068742P | 2014-10-26 | 2014-10-26 | |
| US62/068,742 | 2014-10-26 | ||
| US201562111053P | 2015-02-02 | 2015-02-02 | |
| US62/111,053 | 2015-02-02 | ||
| US201562111590P | 2015-02-03 | 2015-02-03 | |
| US62/111,590 | 2015-02-03 | ||
| US201562128446P | 2015-03-04 | 2015-03-04 | |
| US62/128,446 | 2015-03-04 | ||
| US201562162140P | 2015-05-15 | 2015-05-15 | |
| US62/162,140 | 2015-05-15 | ||
| US201562165535P | 2015-05-22 | 2015-05-22 | |
| US62/165,535 | 2015-05-22 | ||
| US201562169997P | 2015-06-02 | 2015-06-02 | |
| US62/169,997 | 2015-06-02 | ||
| US201562180026P | 2015-06-15 | 2015-06-15 | |
| US62/180,026 | 2015-06-15 | ||
| US201562193347P | 2015-07-16 | 2015-07-16 | |
| US62/193,347 | 2015-07-16 | ||
| US201562205061P | 2015-08-14 | 2015-08-14 | |
| US62/205,061 | 2015-08-14 | ||
| US201562216636P | 2015-09-10 | 2015-09-10 | |
| US62/216,636 | 2015-09-10 | ||
| US201562217470P | 2015-09-11 | 2015-09-11 | |
| US201562217142P | 2015-09-11 | 2015-09-11 | |
| US62/217,470 | 2015-09-11 | ||
| US62/217,142 | 2015-09-11 | ||
| PCT/US2015/049934 WO2016040930A1 (en) | 2014-09-14 | 2015-09-14 | Pharmaceutical compositions comprising a dextromethorphan compound and quinidine for the treatment of agitation in dementia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020116666A Division RU2020116666A (ru) | 2014-09-14 | 2015-09-14 | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2017112747A true RU2017112747A (ru) | 2018-10-15 |
| RU2017112747A3 RU2017112747A3 (ru) | 2019-04-29 |
Family
ID=55459653
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2017112747A RU2017112747A (ru) | 2014-09-14 | 2015-09-14 | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции |
| RU2020116666A RU2020116666A (ru) | 2014-09-14 | 2015-09-14 | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2020116666A RU2020116666A (ru) | 2014-09-14 | 2015-09-14 | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190111047A1 (ru) |
| EP (4) | EP3708168A3 (ru) |
| JP (4) | JP2017531033A (ru) |
| KR (1) | KR20170052684A (ru) |
| CN (3) | CN110664801A (ru) |
| AU (3) | AU2015314710A1 (ru) |
| CA (1) | CA2960031A1 (ru) |
| IL (2) | IL250786A0 (ru) |
| MX (3) | MX2017003066A (ru) |
| MY (1) | MY198587A (ru) |
| PH (1) | PH12017500444A1 (ru) |
| RU (2) | RU2017112747A (ru) |
| SG (2) | SG10201901242PA (ru) |
| TW (2) | TW202106301A (ru) |
| WO (1) | WO2016040930A1 (ru) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2994153A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| CA2994169A1 (en) * | 2015-07-30 | 2017-02-02 | Concert Pharmaceuticals, Inc. | Deuterated morphinan compounds for use in treating agitation |
| EP4335500A3 (en) * | 2016-07-04 | 2024-05-08 | Avanir Pharmaceuticals, Inc. | Methods for the synthesis of deuterated dextromethorphan |
| US11478467B2 (en) | 2017-05-04 | 2022-10-25 | Sreenivasarao Vepachedu | Targeted drug rescue with novel compositions, combinations, and methods thereof |
| CA3100897A1 (en) * | 2018-05-18 | 2019-11-21 | Anavex Life Sciences Corp. | Optimized sigma-1 agonist method of responder selection and treatment |
| KR20210110654A (ko) * | 2019-01-07 | 2021-09-08 | 안테씨프 바이오벤쳐스 투 엘엘씨 | 우울증 치료를 위한 덱스트로메토르판과 부프로피온의 조합 |
| EA202193178A1 (ru) * | 2019-03-18 | 2022-02-21 | Аванир Фармасьютикалз, Инк. | Способы лечения негативных симптомов шизофрении с помощью дейтерированного декстрометорфана и хинидина |
| EP4142729A1 (en) * | 2020-04-27 | 2023-03-08 | Avanir Pharmaceuticals, Inc. | Methods of treating agitation associated with alzheimer's disease |
| CN115245515A (zh) * | 2021-04-27 | 2022-10-28 | 杭州剂泰医药科技有限责任公司 | 一种组合物的医药用途 |
| CN115322150B (zh) * | 2021-05-11 | 2024-05-28 | 深圳信立泰药业股份有限公司 | 氘代右美沙芬氢溴酸盐的固体及其制备方法和医药用途 |
| CN113209042A (zh) * | 2021-05-28 | 2021-08-06 | 珠海润都制药股份有限公司 | 一种氢溴酸右美沙芬硫酸奎尼丁胶囊及其制备方法 |
| JP2024540104A (ja) * | 2021-10-27 | 2024-10-31 | アバニア ファーマシューティカルズ， インコーポレイテッド | アルツハイマー病に関連する激越を治療する方法 |
| US11730706B1 (en) * | 2022-07-07 | 2023-08-22 | Antecip Bioventures Ii Llc | Treatment of depression in certain patient populations |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| US5350756A (en) | 1991-06-17 | 1994-09-27 | Smith Richard A | Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan |
| US5166207A (en) | 1991-06-17 | 1992-11-24 | Neurotherapeutics, Inc. | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders |
| US5366980A (en) | 1991-06-17 | 1994-11-22 | Smith Richard A | Use of dextromethorphan and an oxidase inhibitor to treat dermatitis |
| TW264473B (ru) * | 1993-01-06 | 1995-12-01 | Hoffmann La Roche | |
| ES2268686T3 (es) | 1994-09-22 | 2007-03-16 | Richard Alan Smith | Combinacion de dextrometorfano con quinidina o sulfato de quinina para tratar diversos trastornos de dificil cura. |
| US5874443A (en) | 1995-10-19 | 1999-02-23 | Trega Biosciences, Inc. | Isoquinoline derivatives and isoquinoline combinatorial libraries |
| US5886210A (en) | 1996-08-22 | 1999-03-23 | Rohm And Haas Company | Method for preparing aromatic compounds |
| US5922683A (en) | 1997-05-29 | 1999-07-13 | Abbott Laboratories | Multicyclic erythromycin derivatives |
| ES2352739T3 (es) | 1997-11-21 | 2011-02-22 | Purdue Neuroscience Company | 2-aminoacetamidas sustituidas y el uso de las mismas. |
| BR9909146A (pt) | 1998-03-26 | 2000-12-05 | Shionogi & Co | Derivados de indol apresentando uma atividade antiviral |
| US6509331B1 (en) | 1998-06-22 | 2003-01-21 | Elan Pharmaceuticals, Inc. | Deoxyamino acid compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds |
| FR2784988B1 (fr) | 1998-10-23 | 2002-09-20 | Adir | Nouveaux composes dihydro et tetrahydroquinoleiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| TWI326214B (en) * | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| AU2007212586A1 (en) * | 2006-02-03 | 2007-08-16 | Avanir Pharmaceuticals | Pharmaceutical compositions for treating depression, anxiety and neurodegenerative disorders |
| CA2645041A1 (en) * | 2006-03-07 | 2007-09-13 | University Of Florida Research Foundation, Inc. | Drug adherence monitoring system |
| WO2008097924A2 (en) * | 2007-02-05 | 2008-08-14 | Avanir Pharmaceuticals | Pharmaceutical compositions comprising dextromethorphan analogs for the treatment of neurological disorders |
| CN101687868B (zh) | 2007-05-01 | 2012-12-12 | 康塞特医药品公司 | 吗啡烷化合物 |
| EP3357923B1 (en) * | 2007-05-01 | 2019-11-13 | Concert Pharmaceuticals Inc. | Morphinan compounds |
| EA023962B1 (ru) * | 2008-09-19 | 2016-07-29 | Консерт Фармасьютикалз Инк. | Дейтерированные морфинановые соединения |
| EP3603674B1 (en) * | 2008-10-30 | 2025-02-26 | Sun Pharmaceutical Industries, Inc. | Combination of morphinan compounds and antidepressant for the treatment of intractable and chronic pain |
| CA2743902C (en) * | 2008-11-14 | 2016-09-20 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| NZ758432A (en) * | 2013-11-05 | 2021-07-30 | Antecip Bioventures Ii Llc | Compositions and methods comprising bupropion or related compounds and dextromethorphan |
-
2015
- 2015-09-14 RU RU2017112747A patent/RU2017112747A/ru not_active Application Discontinuation
- 2015-09-14 EP EP20159783.8A patent/EP3708168A3/en not_active Withdrawn
- 2015-09-14 TW TW109114123A patent/TW202106301A/zh unknown
- 2015-09-14 EP EP15840718.9A patent/EP3193872A4/en not_active Withdrawn
- 2015-09-14 CA CA2960031A patent/CA2960031A1/en active Pending
- 2015-09-14 US US15/510,498 patent/US20190111047A1/en not_active Abandoned
- 2015-09-14 JP JP2017533726A patent/JP2017531033A/ja active Pending
- 2015-09-14 EP EP22195837.4A patent/EP4166141A1/en active Pending
- 2015-09-14 SG SG10201901242PA patent/SG10201901242PA/en unknown
- 2015-09-14 SG SG11201701645WA patent/SG11201701645WA/en unknown
- 2015-09-14 CN CN201910903770.XA patent/CN110664801A/zh active Pending
- 2015-09-14 TW TW104130311A patent/TW201613591A/zh unknown
- 2015-09-14 CN CN202311175974.9A patent/CN117427077A/zh active Pending
- 2015-09-14 RU RU2020116666A patent/RU2020116666A/ru unknown
- 2015-09-14 EP EP21178170.3A patent/EP3932907A3/en not_active Withdrawn
- 2015-09-14 AU AU2015314710A patent/AU2015314710A1/en not_active Abandoned
- 2015-09-14 MX MX2017003066A patent/MX2017003066A/es unknown
- 2015-09-14 WO PCT/US2015/049934 patent/WO2016040930A1/en active Application Filing
- 2015-09-14 CN CN201580049454.0A patent/CN107072990A/zh active Pending
- 2015-09-14 KR KR1020177009991A patent/KR20170052684A/ko not_active Ceased
- 2015-09-14 MY MYPI2017000321A patent/MY198587A/en unknown
-
2017
- 2017-02-26 IL IL250786A patent/IL250786A0/en unknown
- 2017-03-08 MX MX2022008181A patent/MX2022008181A/es unknown
- 2017-03-08 MX MX2021010696A patent/MX2021010696A/es unknown
- 2017-03-09 PH PH12017500444A patent/PH12017500444A1/en unknown
-
2019
- 2019-10-08 US US16/596,236 patent/US20200289499A1/en not_active Abandoned
- 2019-11-06 JP JP2019201410A patent/JP2020019818A/ja not_active Withdrawn
-
2020
- 2020-05-18 IL IL274742A patent/IL274742A/en unknown
- 2020-12-15 AU AU2020289733A patent/AU2020289733A1/en not_active Abandoned
-
2021
- 2021-03-08 JP JP2021036318A patent/JP7360409B2/ja active Active
-
2022
- 2022-12-06 AU AU2022283671A patent/AU2022283671B2/en active Active
-
2023
- 2023-04-24 US US18/305,589 patent/US20240082237A1/en active Pending
- 2023-06-12 JP JP2023096152A patent/JP2023105265A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017112747A (ru) | Фармацевтические композиции, содержащие декстрометорфановое соединение и хинидин для лечения возбуждения при деменции | |
| MX2024010140A (es) | Nuevos metodos. | |
| EA201791019A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| ME02910B (me) | Spojevi tetrahidropirolotiazina | |
| TN2017000119A1 (en) | Indole carboxamides compounds useful as kinase inhibitors | |
| EA201791872A1 (ru) | Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение | |
| EA201790088A1 (ru) | Ингибиторы syk | |
| EA201491329A1 (ru) | 4,4-дизамещенные 1,4-дигидропиримидины и их применение в качестве лекарственных препаратов для лечения гепатита b | |
| EA201791199A1 (ru) | Способ лечения болезни альцгеймера | |
| RU2017105353A (ru) | Соединения | |
| EA201790305A1 (ru) | КОМБИНИРОВАННАЯ ТЕРАПИЯ БОЛЕЗНИ АЛЬЦГЕЙМЕРА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ МОНОКЛОНАЛЬНЫХ АНТИТЕЛ К N3pGlu АБЕТА И ИНГИБИТОРА BACE | |
| EA201691789A1 (ru) | Фармацевтические композиции и соли 1,2,4-оксадиазолбензойной кислоты | |
| JP2016510326A5 (ru) | ||
| EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| CY1124115T1 (el) | Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| RU2019110980A (ru) | Фармацевтические композиции, содержащие 15-гэпк, и способы лечения астмы и заболеваний легких с их применением | |
| JP2015516419A5 (ru) | ||
| RU2016112257A (ru) | Композиция для лечения гипертензии и/или фиброза | |
| EA201591021A1 (ru) | 4-гидрокси-2-метил-5-(пропан-2-илиден)циклогекс-3-энекарбальдегид в профилактике и лечении когнитивных, нейродегенеративных или нейронных заболеваний | |
| RU2020120876A (ru) | Фармацевтическая композиция, содержащая антагонист минералокортикоидных рецепторов, и ее применение | |
| MA39448A1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| EP2870971A4 (en) | DRUGS FOR THE PREVENTION / TREATMENT OF EYE DISEASES | |
| RU2015131803A (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20200730 |